The Business Research Company’s report on the Malignant Mesothelioma Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the malignant mesothelioma industry?
The increasing clinical research and development efforts are expected to drive the growth of the malignant mesothelioma market going forward. Clinical research and development (R&D) efforts involve conducting scientific studies and trials to develop new drugs, treatments, and medical devices. These efforts include testing new products’ safety, efficacy, and potential side effects through controlled clinical trials. The increasing clinical research and development efforts are due to the growing demand for new and improved treatments, especially with the rising prevalence of chronic diseases and complex conditions. Research and development efforts drive malignant mesothelioma by accelerating advances in diagnostics, treatments, and targeted therapies, fostering innovative approaches to improve early detection, enhance survival rates, and develop more effective, less invasive treatment options. For instance, in January 2025, according to Anadolu Agency, a Turkey-based state-run news agency, clinical trials make up nearly 40% of the U.S. pharmaceutical research budget, totaling approximately $7 billion annually. Therefore, the increasing research and development efforts are driving the growth of the malignant mesothelioma market.
Access Your Free Sample of the Global Malignant Mesothelioma Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22046&type=smp
What is the estimated market size of the malignant mesothelioma sector by 2029, based on current forecasts?
The malignant mesothelioma market size has grown strongly in recent years. It will grow from $2.46 billion in 2024 to $2.63 billion in 2025 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing investments in oncology research, rise in asbestos-related litigation cases, rise in hospital investments, rise in the aging population, and grow in ai-driven drug discovery platforms.
The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.41 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing focus on personalized medicine, rising utilization of minimally invasive surgical procedures, rising healthcare expenditure, and growing number of clinical trials. Major trends in the forecast period include advancements in immunotherapy, personalized medicine, early detection initiatives, minimally invasive surgical techniques, and regulatory approvals.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22046&type=smp
Who are the top players in the malignant mesothelioma market?
Major companies operating in the malignant mesothelioma market are AstraZeneca, NYU Langone Health, Mayo Foundation for Medical Education and Research, The University of Chicago Medical Center, Ono Pharmaceutical Co., Ltd., Dana-Farber Cancer Institute, UVA Health, PharmaMar, Healthcare Global Enterprises Ltd., Fujirebio Europe, Cancer Healer Center, Rosetta Genomics, Mesothelioma UK, The Mesothelioma Center, Oncoplus, Mesothelioma Research Foundation of America, Pleural Mesothelioma Center
What are the major trends in the malignant mesothelioma market?
Major companies operating in the malignant mesothelioma market are focusing on developing advanced treatment options, such as monoclonal antibody treatments, to inhibit tumor growth and improve treatment precision. Monoclonal antibodies refer to laboratory-made proteins that mimic the immune system’s ability to detect and target specific antigens, such as those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval marks Opdivo as a new treatment option for this condition, where no standard treatments were previously established. Opdivo was designated an orphan drug for this indication, highlighting its potential to address a significant medical need.
Which geography holds the highest malignant mesothelioma market share?
North America was the largest region in the malignant mesothelioma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the malignant mesothelioma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/malignant-mesothelioma-global-market-report
How do different segments contribute to the overall expansion of the malignant mesothelioma market?
The malignant mesothelioma market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy
2) By Route Of Administration: Oral, Intravenous, Injectable, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies
4) By End-User: Hospitals, Oncology Clinics, Rehabilitation Centres, Research Laboratories
Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy
2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy
3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery
4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy
5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22046
What defines the structure and scope of the malignant mesothelioma market?
Malignant mesothelioma is a rare and aggressive type of cancer that primarily affects the mesothelium, a thin layer of tissue that covers most of the internal organs. It most commonly develops in the lining of the lungs (pleura) but can also occur in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The main risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral once widely used in construction and manufacturing.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
